Assessment of a Polygenic Risk Score in Screening for Prostate Cancer

In a prostate cancer screening program involving participants in the top decile of risk as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been identified with the use of PSA or MRI. (Funded by the European Research Council Seventh Framework Program and others; BARCODE1 ClinicalTrials.gov number, NCT03857477.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-04-09
DOI
https://doi.org/10.1056/nejmoa2407934
Citations
58
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
88.06

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessment of a Polygenic Risk Score in Screening for Prostate Cancer

Nafisa Hussain, Elizabeth Bancroft, Susan Merson, Angela Wood et al.
58 citations
New England Journal of Medicine
Prostate Cancer Diagnosis and Treatment
88.06
article

Assessment of a Polygenic Risk Score in Screening for Prostate Cancer

Nafisa Hussain, Elizabeth Bancroft, Susan Merson, Angela Wood, Rosalind A. Eeles, Samuel J. Withey, Justyna M. Sobczak, Bradley Russell, Ann-Britt Jones, Tokhir Dadaev, Nicholas David James, Jana McHugh, Dean Y. Huang, Reshma Rageevakumar, Kathryn Myhill, Syed Arshad Hussain, Sarah Benafif, Michelle Ferris, Matthew Hogben, Aslam Sohaib, Fionnuala Croft, Questa Karlsson, Kaljit Kaur, Zsofia Kote‐Jarai, Mark N. Brook, Naami Charlotte Mcaddy, Edward Saunders, Samantha Bennett, Imran Rafi, Netty Kinsella, Barbara Benton, Sarah Wakerell, Eva McGrowder, Sibel Saya, Richard Nicholson, Andrea Osborne, Claire McNally, Nening M. Dennis, Dhruv Patel, Alison Thwaites, Nora Pashayan, Stephen Hazell, F. Mutch, Elizabeth Page, Denzil James, Natalie Taylor, Declan J. Cahill, Pardeep Kumar, Lenita Kingston
article en
58 citations

Abstract

In a prostate cancer screening program involving participants in the top decile of risk as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been identified with the use of PSA or MRI. (Funded by the European Research Council Seventh Framework Program and others; BARCODE1 ClinicalTrials.gov number, NCT03857477.).

New England Journal of MedicineVol. 392(14)
Royal Marsden NHS Foundation Trust (GB), University College London Hospitals NHS Foundation Trust (GB), The University of Melbourne (AU), St George's, University of London (GB), King's College London (GB), University of Cambridge (GB), Institute of Cancer Research (CA), University College London (GB)
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Peacock Trust, Royal Marsden Cancer Charity, Cancer Research UK, European Research Council
Good health and well-being
Openalex Percentile: Top 0%
Prostate Cancer Diagnosis and Treatment
88.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.